The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19

Introduction: Infection with SARS-CoV-2 induces a prothrombotic state in patients, by the combination of hyperinflammatory response and hypoxia. In Cuba, the drug called Jusvinza, based on an immunomodulatory peptide, is used for the treatment of patients with COVID-19, who present signs and symptom...

Descripció completa

Dades bibliogràfiques

Autors principals:	Rafael Venegas Rodríguez, Anabel Serrano Díaz, Rubén Peña Ruiz, Raúl Santana Sánchez, Aliusha Rittoles Navarro, Inti Grecesqui Cruz, Liam Manuel Pérez Aguilera, Anadys Segura Fernández, Mabel Hernández-Cedeño, Leticia Rosario Cruz, Deyli Chacón Montano, Gillian Martínez-Donato, Gerardo Guillén-Nieto, María del Carmen Domínguez Horta
Format:	Artigo
Idioma:	Espanhol
Publicat:	Editorial Ciencias Médicas - ECIMED 2021-11-01
Col·lecció:	Revista Cubana de Medicina Militar
Matèries:	covid-19 hiperinflamación hipercoagulación hsp60 cigb-258 jusvinza.
Accés en línia:	http://www.revmedmilitar.sld.cu/index.php/mil/article/view/1675
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!